3S Guojian Pharmaceutical

3S Guojian Pharmaceutical is a leading Chinese biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic antibody drugs. As the biologics arm of 3SBio, the company established itself as a pioneer by launching Yisaipu, the first recombinant human TNF-alpha receptor-antibody fusion protein in China. 3S Guojian operates one of the largest mammalian cell culture manufacturing facilities in the country, supporting a robust pipeline focused on autoimmune diseases, oncology, and ophthalmology. The company is listed on the Shanghai Stock Exchange STAR Market and continues to expand its portfolio through both internal R&D and strategic global partnerships.